Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Comment by EbbFlow88on Apr 23, 2022 9:53am
101 Views
Post# 34626036

RE:GUD and INFLATION

RE:GUD and INFLATIONYes, that has been the truth but look forward.

Currently, if you subtract cash and investmenets (which have been earning a double digit return) you are left with a market cap of around $270M. Divide cash flow of 40M by market cap and you get about 15% cash yield. 

Even with cash and investments earning nothing then you get your return of 7.5% a year over time which will sooner or later be reflected in the stock price theoretically. 

Except that cash is not sitting idle. Plenty is invested in funds that have done well, or debt that is achieving double digit returns and management has put a lot of idle cash to work with Exelon. 

Therefore, as aluded to before, if management can put that cash and divest from the funds and reinvest at similar returns then you can easily forecast 15% return per annum over time.

That will be a great hedge against inflation.

Also, notice how when the market is selling off with higher interest rates that GUD is steady. I believe thats for two reasons. 1) There's some room to raise prices of our products and 2) the optionality of cash on the balance sheet is becoming more useful. 

What once was a hinderence with cheap interest rates where anyone could raise cheap money, now is becoming more expensive and we have plenty of cash when valuations are getting squeezed.


<< Previous
Bullboard Posts
Next >>